A Study To Compare The Amount Of Tasocitinib (CP-690,550) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Three Different Tablet Versions Of Tasocitinib (CP-690,550)

• Drug: Treatment A
  
  Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
• Drug: Treatment B
  
  Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
• Drug: Treatment C
  
  Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).

• Experimental: Sequence 1
  
  Interventions:
  

  • Drug: Treatment A
  • Drug: Treatment B
  • Drug: Treatment C
• Experimental: Sequence 2
  
  Interventions:
  

  • Drug: Treatment A
  • Drug: Treatment C
  • Drug: Treatment B
• Experimental: Sequence 3
  
  Interventions:
  

  • Drug: Treatment B
  • Drug: Treatment C
  • Drug: Treatment A
• Experimental: Sequence 4
  
  Interventions:
  

  • Drug: Treatment B
  • Drug: Treatment A
  • Drug: Treatment C
• Experimental: Sequence 5
  
  Interventions:
  

  • Drug: Treatment C
  • Drug: Treatment A
  • Drug: Treatment B
• Experimental: Sequence 6
  
  Interventions:
  

  • Drug: Treatment C
  • Drug: Treatment B
  • Drug: Treatment A

Inclusion Criteria:

• Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive.
• Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight for males>50 kg (110 lbs). For females, total body weight >45 kg (99 lbs).
• No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).

Exclusion Criteria:

• Evidence of any clinically significant illness, medical condition, or disease.
• Evidence or history of any clinically significant infections within the past 3 months.
• Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.